PGEN Precigen, Inc.

Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.

MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.

ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.

Precigen, Inc. (NASDAQ:PGEN) announced on September 21 that the FDA granted Platform Technology Designation to AdenoVerse, the technology behind the approved medicine PAPZIMEOS. The designation creates opportunities to reuse manufacturing and preclinical knowledge in future drug applications, potentially reducing work that would otherwise need to be repeated. For Precigen, Inc. (NASDAQ:PGEN), the investment question is […]

Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.

Precigen (PGEN) is back in focus after the United States Food and Drug Administration granted platform technology designation to its AdenoVerse immunotherapeutic platform, which underpins the recently approved PAPZIMEOS therapy. The recent FDA platform technology designation and the earlier approval of PAPZIMEOS have coincided with a sharp shift in market sentiment toward Precigen, with the share price delivering an 81.07% year-to-date return and a very large 3-year total shareholder return...

Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.

Precigen (NasdaqGS:PGEN) said the FDA has granted platform technology designation to its AdenoVerse immunotherapeutic platform. The designation applies to the AdenoVerse platform rather than a single drug, covering multiple potential future product candidates across indications. FDA platform technology status can allow certain data and review learnings from one product to support later candidates built on the same backbone. The new FDA platform technology designation for AdenoVerse sits...

Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.

Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.

Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.

Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.

VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.

Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.

Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

Precigen has seen its stock climb sharply in recent years, which naturally puts the focus on what investors are paying for each dollar of its sales. With the share price at US$7.87 at the last close, the open question is whether that level is adequately supported by the company’s current revenue base. Over the past 3 years the stock has returned about 4.6x, which puts a lot of weight on whether its sales profile can carry that kind of re-rating. For a business like Precigen, future outcomes...

KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.

Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.

GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.

DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.

PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.

Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.

SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.

VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.

Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.

FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.

Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.

Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.

Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.

Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.

Event driven interest in Precigen stock Fresh attention on Precigen (PGEN) follows commentary that new drug approvals and pipeline progress could support the Zacks Biomedical and Genetics industry, with Papzimeos highlighted for recurrent respiratory papillomatosis. Investors are weighing how Papzimeos commercial performance and Precigen's broader gene and cell therapy pipeline might relate to recent share price moves and the company’s current valuation profile. At a latest share price of...

Recent commentary on the Zacks Biomedical and Genetics industry highlighted Precigen’s past momentum, citing steady commercial performance from its sole marketed drug Papzimeos for recurrent respiratory papillomatosis and encouraging pipeline progress despite a challenging macro backdrop. The focus on Papzimeos as a single commercial pillar underscores both the company’s concentration risk and the importance of its broader development portfolio to diversify future revenue sources. We’ll now...

Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.

GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.

Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.

Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.

ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.

Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.

NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.

argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.

Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Precigen’s latest earnings matter for investors Precigen (PGEN) drew fresh attention after its second quarter 2026 earnings, where revenue reached US$54.98 million and net income came in at US$20.07 million, following the commercial launch of PAPZIMEOS. See our latest analysis for Precigen. Precigen’s latest earnings arrived alongside strong share price momentum, with a 30 day share price return of 28.95% and a 90 day share price return of 65.30%. The 1 year total shareholder return of...

PAPZIMEOS revenue surged 145.8% sequentially as company posts first profitable quarter.